Why this trial matters: First global Phase III success in a disease with no approved targeted therapy Could change management of systemic symptoms and glandular dysfunction Gene Therapy Phase III in Epidermolysis Bullosa Shows Healing Benefit A Phase III gene therapy trial for epidermolysis bullosa (EB) demonstrated significantly better wound healing, less pain, and reduced itching compared with standard care, and the therapy earned FDA approval in 2025 a major advance for this previously untreatable genetic skin disorder
At-home ovulation test kits can also help women see when they are ovulating
The interesting part over the next 1218 months will be watching who can scale repeatably without creating compliance drift, turnaround delays, or variability across sites
What follows covers the three primary injection sites in detail, the science behind absorption differences between sites, step-by-step injection technique, a complete rotation schedule you can follow week by week, troubleshooting for common injection site problems, and the specific considerations that make retatrutide administration different from other GLP-1 receptor agonists
The failure to distinguish between these two molecules is the primary source of misinformation surrounding TB-500s safety profile
